A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-Lowering Therapy.

Trial Profile

A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-Lowering Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Lomitapide (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Aegerion Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Aug 2013 Lomitapide has been approved in Europe based on results from this trial according to an Aegerion Pharmaceuticals media release.
    • 31 May 2013 The CHMP has adopted a positive opinion recommending marketing authorisation for lomitapide, according to an Aegerion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top